ANONYMOUS: "NCT02631551 on 2017_05_18: ClinicalTrials.gov Archive", 18 May 2017 (2017-05-18), XP055444418, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02631551/2017_05_18> [retrieved on 20180125] (B1)

ANONYMOUS: "NCT02870205 on 2017_05_03: ClinicalTrials.gov Archive", 3 May 2017 (2017-05-03), XP055444415, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02870205/2017_05_03> [retrieved on 20180125] (B1)

ANONYMOUS: "To Study GSP 301 in Patients With Seasonal Allergic Rhinitis - Study Results - ClinicalTrials.gov", 28 June 2017 (2017-06-28), XP055445229, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/results/NCT02318303?term=NCT02318303&rank=1 =X4370156#othr> [retrieved on 20180126] (B1)

US-A1- 2016 287 612 (B1)

KALINER ET AL: "Azelastine and olopatadine in the treatment of allergic rhinitis", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, ARLINGTON HEIGHTS, IL, US, vol. 103, no. 5, 1 November 2009 (2009-11-01), pages 373 - 380, XP026960456, ISSN: 1081-1206, [retrieved on 20091101] (B1)

US-A1- 2015 099 725 (B1)

GLENMARK PHARMACEUTICALS: "Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301,", 29 March 2017 (2017-03-29), XP055444412, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/glenmark-pharmaceuticals-reports-positive-results-from-a-phase-3-trial-of-gsp-301-mometasoneolopatadine-fixed-dose-combination-nasal-spray-in-seasonal-allergic-rhinitis-300431125.html> [retrieved on 20180125] (B1)